(Q37765291)

English

Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization

scientific article published on June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

revascularization

1 reference

based on heuristic

inferred from title

author name string

Fabio Mangiacapra

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Emanuele Barbato

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

publication date

1 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Biomarkers in Medicine

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

421-434

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Platelet activation and atherothrombosis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet accumulation in experimental angioplasty: time course and relation to vascular injury

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin improves endothelial dysfunction in atherosclerosis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin protects low density lipoprotein from oxidative modification

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Narrative review: aspirin resistance and its clinical implications

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Ticlopidine and clopidogrel

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Methods for the measurement of platelet function

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists--in vitro experience

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibati

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.56

21 January 2018

Identifiers

10.2217/BMM.10.56

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37765291&oldid=1727194525"